Scilex Holding (SCLX) Equity Average (2020 - 2026)
Scilex Holding (SCLX) posted quarterly Equity Average of -$230.9 million for Q1 2026, down 14.28% year-over-year from -$269.4 million in Q1 2025, and down 20.05% on a QoQ basis from -$192.4 million in Q4 2025.
Scilex Holding (SCLX) Equity Average (2020 - 2026) Analysis & Trends
Scilex Holding (SCLX) has reported Equity Average for 7 consecutive years, with -$230.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Equity Average fell 14.28% year-over-year to -$230.9 million; the TTM figure through Mar 2026 stood at -$230.9 million (down 14.28% YoY), while the FY2025 annual figure was -$200.2 million, down 9.53% from the prior year.
- Equity Average came in at -$230.9 million for Q1 2026 at Scilex Holding, down from -$192.4 million in the prior quarter.
- The five-year high for Equity Average was $23.7 million in Q1 2023, with the low at -$241.8 million in Q2 2022.
- Average Equity Average over 5 years is -$169.6 million, with a median of -$202.1 million recorded in 2025.
- Across the five-year window, Equity Average plunged 2824.72% in 2022 and surged 110.39% in 2023, its largest moves.
- Year by year, Equity Average stood at -$96.6 million in 2022, then slumped by 73.75% to -$167.8 million in 2023, then decreased by 20.37% to -$202.0 million in 2024, then climbed by 4.76% to -$192.4 million in 2025, then slipped by 20.05% to -$230.9 million in 2026.
- According to Business Quant data, Equity Average over the past three periods registered -$230.9 million, -$192.4 million, and -$213.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 28.87 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 81.37 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -4.96 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 49.27 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 8.92 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 23.11 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 88.29 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | -230.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -230.93 Mn |
| Dec 31, 2025 | -192.36 Mn |
| Sep 30, 2025 | -212.96 Mn |
| Jun 30, 2025 | -230.24 Mn |
| Mar 31, 2025 | -202.06 Mn |
| Dec 31, 2024 | -201.98 Mn |
| Sep 30, 2024 | -213.00 Mn |
| Jun 30, 2024 | -202.24 Mn |
| Mar 31, 2024 | -181.36 Mn |
| Dec 31, 2023 | -167.80 Mn |
| Sep 30, 2023 | -76.13 Mn |
| Jun 30, 2023 | 10.75 Mn |
| Mar 31, 2023 | 23.66 Mn |
| Dec 31, 2022 | -96.58 Mn |
| Sep 30, 2022 | -240.75 Mn |
| Jun 30, 2022 | -241.83 Mn |
| Mar 31, 2022 | -227.72 Mn |
| Dec 31, 2021 | -116.85 Mn |
| Sep 30, 2021 | -9.11 Mn |
| Jun 30, 2021 | -8.27 Mn |